Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    Tucidinostat

    go.drugbank.com/drugs/DB06334
    Investigational

  2. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  3. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    H2S is an endogenous gaseous transmitter that exhibits anti-inflammatory and antiapoptotic properties. … Along with its hydrate form, sodium sulfide releases hydrogen sulfide (H2S) when in contact with moist air.

  4. Drug

    Regramostim

    go.drugbank.com/drugs/DB05386
    Investigational

    GM-CSF is found associated with extracellular matrix and in membrane-bound formats too.

  5. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  6. Drug

    SC-236

    go.drugbank.com/drugs/DB14059
    Experimental

    SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374

  7. Drug

    Cypermethrin

    go.drugbank.com/drugs/DB13721
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Cyfluthrin

    go.drugbank.com/drugs/DB13828
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Stevioside

    go.drugbank.com/drugs/DB16882
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.